查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乳腺病變定位市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190148

乳腺病變定位市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Breast Lesion Localization Methods Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，乳腺病變定位市場預計將以 11.2% 的複合年增長率增長。

COVID-19 大流行嚴重影響了所研究的市場，大流行導致的封鎖和非緊急程序的暫停導致醫院、診所和診斷中心的就診人數顯著下降。我是。 根據 2021 年 10 月發表在《預防醫學》上的一項研究，全球乳腺癌篩查和參與受到了大流行的影響。 許多國家，包括加拿大、荷蘭、德國、意大利、英國和澳大利亞，已暫停乳腺癌篩查計劃，以防止冠狀病毒污染和人口傳播。 因此，篩查和診斷的延誤影響了大流行期間的市場增長。 然而，隨著 COVID-19 限制的解除、腫瘤科和醫院的重新開放、乳腺癌手術的增加以及政府對乳腺癌篩查和治療的宣傳計劃，研究中的市場預計將在未來反彈增長三到四年。將是

推動市場增長的其他因素包括乳腺癌和乳腺癌手術患病率的上升、乳腺病變定位技術的進步，以及公眾意識的提高和對乳腺癌早期發現的需求。

隨著用於識別和治療乳腺病變和乳腺癌的外科手術和成像技術的進步，乳腺病變定位已成為一種常見的程序。 由於全球乳腺癌負擔不斷增加，預計它將引領市場。 根據 GLOBOCAN 2020 報告，預計到 2040 年將診斷出約 3,025,471 例乳腺癌新病例。 隨著乳腺癌患者數量的增加，對乳房定位手術的需求不斷增加，推動了市場的增長。

政府加大力度提高公眾對乳腺癌的認識，預計也會增加對乳腺癌診斷和治療的需求。 2021 年 10 月，Wefralife 和德國粉紅絲帶 (NPO) 發起了“乳腺癌影響我們所有人”活動，以提高人們對乳腺癌的認識並普及乳房護理應用。 BreastCare 是一款免費的多語言應用程序，以 7 種語言提供與乳腺癌早期檢測和預防相關的多媒體內容。

此外，乳房定位方法的技術不斷進步為公司創造了機會，並增加了執行該程序的先進設備的可用性。 2021 年 5 月，美國 FDA 批准了 MOLLI Surgical 用於乳腺癌手術的新型無線立體定向技術，使放射科醫生能夠快速準確地標記病灶，幫助外科醫生高效地定位和切除病灶。 這個新平台包括可植入標記物、檢測棒和可視化平板電腦，以幫助改善腫瘤定位。

因此，由於乳腺癌負擔增加、政府舉措增加和產品批准等因素，預計在預測期內會增長。 然而，諸如嚴格的監管指南和與乳腺病變定位方法相關的高成本等因素預計將阻礙預測期內的市場增長。

主要市場趨勢

電線本地化部分有望佔據重要的市場份額

在乳腺病變定位方面，由於人口增長導致乳腺癌發病率上升、技術先進的產品增加以及產品發布增加等因素，在預測期內，線材定位領域將出現顯著增長。

與其他乳腺病變定位技術相比，鋼絲定位還具有價格低廉、準確且有效的優勢，有望在乳腺癌治療中得到越來越多的採用。 預計這也將對該領域的增長產生積極影響。

鋼絲定位法是定位乳房腫塊和異常的最廣泛使用的方法。 這種方法使用一根細線來精確定位腫塊或異常的確切位置。 又稱間苗法或針狀法。 2021 年 2 月發表在 Journal of Personalized Medicine 上的一篇論文證實，導線定位方法可以在不同類型的成像引導下（乳房 X 線攝影、超聲、磁共振成像）進行。 該手術是治療不可觸及的乳腺病變最常見的手術，據報導清潔邊緣為 70.8% 至 87.4%。 預計此類研究將增加乳腺癌患者治療的採用率，並促進該領域的增長。

乳腺癌負擔的增加、乳房手術數量的增加以及導絲定位方法在診斷和治療過程中的廣泛採用是導絲定位領域的主要增長動力。 根據 2022 年 9 月發表在《乳腺癌研究與治療》雜誌上的一篇論文，在 60 歲以上的女性中，德國 175 厘米以上女性的乳腺癌患病率為 6.8%，171-175 厘米女性的乳腺癌患病率為 12.2%。說是%。 由於乳腺癌患者的高負擔，早期發現和有效治療的需求不斷增加，預計將進一步推動該細分市場的增長。

此外，對採用關鍵戰略進入市場的公司的更多關注也有助於市場增長。 例如，2021 年 1 月，Hologic, Inc. 以 6400 萬美元收購了 Somatex Medical Technologies。 此次收購將幫助該公司提供更廣泛的創新乳腺健康解決方案，並通過活檢部位標記和定位技術擴展其乳腺標記產品組合。 此外，通過此次收購，公司將擴大其在德國的直銷渠道及其區域和全球分銷商網絡，並加強其在歐洲的銷售隊伍。

因此，由於上述因素（例如女性乳腺癌患病率較高以及線定位技術的採用率增加），預計研究領域在預測期內將會增長。

北美有望主導市場

北美在過去幾年一直主導著乳腺病變定位市場，預計在預測期內也將呈現類似的趨勢。 這主要是由於乳腺癌患者的高負擔、強大的醫療保健基礎設施和對乳腺癌的認識不斷提高。

在北美，由於乳腺癌的高患病率和發病率、穩健的醫療保健基礎設施以及更好的報銷方案，預計美國在預測期內將佔據所研究市場的很大份額。 根據 BCRF 發布的 2022 年統計數據，預計 2022 年美國女性將診斷出約 287,850 例乳腺癌新病例。 根據同一消息來源，在美國，女性在其生命中的某個階段患上乳腺癌的平均風險為 13%。 近年來，美國乳腺癌的發病率每年增加0.5%。 根據加拿大癌症協會發布的 2022 年統計數據，預計到 2022 年將有大約 28,600 名加拿大女性被診斷出患有乳腺癌。 因此，預計乳腺癌患者的增加將推動對治療乳腺癌的診斷和外科手術的需求，推動乳腺病變定位市場的增長多年。

此外，該地區不斷增加的產品批准預計將增加市場上本地化設備的可用性，從而推動預測期內的市場增長。 例如，2022 年 7 月，Merit Medical System 將招募其首位患者參加上市後觀察研究，以證明 SCOUT 的好處，SCOUT 是一種用於標記乳腺腫瘤、活檢部位和淋巴結的無線雷達引導立體定位設備。

因此，由於上述因素（例如該地區的高乳腺癌負擔和產品批准增加），預計研究市場將在預測期內增長。

競爭格局

乳腺病變定位市場是整合的，由幾家主要參與者組成。 就份額而言，一些主要參與者目前主導著市場。 研究的市場參與者包括 Becton、Dickinson and Company、Hologic Inc.、Cook Medical、Merit Medical 和 STAYLABS。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 調查先決條件和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 乳腺癌發病率和乳腺癌手術的增加
    • 乳腺病變定位的技術進步
    • 人們越來越意識到早期發現乳腺癌的必要性
  • 市場製約因素
    • 與乳腺病變定位方法相關的高成本
    • 嚴格的監管要求
  • 行業吸引力 - 波特五力分析
    • 新進入者的威脅
    • 買家的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（金額基礎：百萬美元）

  • 通過本地化方法
    • 電線定位
    • 放射性同位素
    • 定位磁性示蹤劑
    • 其他本地化方法
  • 按地區列出
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Becton, Dickinson and Company
    • Hologic Inc.（SOMATEX Medical Technologies）
    • Cook Medical
    • Merit Medical（Cianna Medical）
    • STERYLAB SRL
    • Danaher Corporation（Leica Biosystems）
    • Theragenics Corporation（CP Medical Inc.）
    • Elucent Medical
    • Tsunami SRL
    • MDL SRL
    • MOLLI Surgical
    • Argon Medical Devices
    • Mermaid Medical A/S

第7章 市場機會與今後動向

簡介目錄
Product Code: 67726

The breast lesion localization methods market is expected to register a CAGR of 11.2% during the forecast period.

The COVID-19 pandemic severely impacted the market studied, as footfall in hospitals, clinics, and diagnostics centers decreased significantly due to the pandemic-resultant lockdown and the suspension of non-urgent procedures. As per a research study published in Preventive Medicines in October 2021, global breast cancer screening and participation were impacted by the pandemic. Many nations, such as Canada, the Netherlands, Germany, Italy, United Kingdom, and Australia, halted their breast screening programs to prevent the contamination and transmission of coronavirus among the population. Thus, the delayed screening and diagnostic procedures impacted the market growth during the pandemic. However, with the released COVID-19 restrictions, reopened oncology care units and hospitals, as well as an increased number of breast cancer surgical procedures and growing awareness programs by the government regarding breast cancer screening and treatment, the studied market is expected to regain its growth over the next 3-4 years.

Other factors, such as the rising prevalence of breast cancer and breast cancer surgeries, technological advancements in breast lesion localization, and increasing awareness and need for early detection of breast cancer among the population, are boosting the market growth.

The localization of breast lesions has emerged as a common procedure with advancements in the surgical and imaging techniques used to identify and treat breast injuries or breast cancer over time. The increasing burden of breast cancer worldwide is expected to drive the market. According to GLOBOCAN 2020 report, about 3,025,471 new breast cancer cases are expected to be diagnosed by 2040. The anticipated increase in the number of people who have breast cancer raises the demand for breast lesion localization procedures, propelling the market growth.

The increasing government initiatives to raise awareness regarding breast cancer among the population are also expected to increase the demand for breast cancer diagnosis and treatment. In October 2021, Wefra Life and Pink Ribbon Germany (a non-profit organization) launched a Breast Cancer Affects Us All campaign to raise awareness about breast cancer and promote breast care applications among the population. Breast Care is a free multilingual app that provides multimedia content in seven different languages that cover all pertinent aspects of early breast cancer detection and prevention.

Furthermore, the rising technological advancements in breast lesion localization methods are creating opportunities for companies, along with increasing the availability of advanced devices for conducting procedures. In May 2021, United States FDA approved MOLLI Surgical's new wire-free localization technology for breast cancer surgery that allows radiologists to mark lesions rapidly and precisely and helps surgeons locate and remove lesions efficiently. This new platform includes an implantable marker, detection wand, and visualization tablet, which help improve tumor localization.

Therefore, factors such as the increasing burden of breast cancer, rising government initiatives, and approval of products are expected to grow over the forecast period. However, factors such as strict regulatory guidelines and high costs associated with breast lesion localization methods are expected to hinder the market's growth over the forecast period.

Key Market Trends

Wire Localization Segment Expected to Hold a Significant Market Share

The wire localization segment is expected to witness significant growth in the breast lesion localization methods market over the forecast period owing to factors such as the rising prevalence of breast cancer among the population, growing technologically advanced products, and rising product launches.

Additionally, the advantages offered by the wire localization method, such as being less expensive, more accurate, and more effective than other breast lesion localization techniques, are also expected to increase its adoption during breast cancer treatment. This factor is also expected to impact the growth of the segment positively.

The wire localization method is the most widely used procedure for locating lumps or abnormalities in the breast. This procedure involves using a fine wire to determine the lump's or abnormality's exact location. It is also known as the fine-wire or needle localization method. As per an article published in the Journal of Personalized Medicine in February 2021, it has been observed that wire localization procedures can be performed under different kinds of image guidance (mammographic, sonographic, and magnetic resonance imaging). This procedure is the most common technique for non-palpable breast lesions, with clean margins reported between 70.8% and 87.4%. Such research is expected to increase its adoption for treating breast cancer among patients, thereby boosting segment growth.

The growing burden of breast cancer, an increasing number of breast surgeries, and the wide adoption of the wire localization method in diagnostic and treatment procedures are major growth factors for the wire localization segment. According to an article published in the Breast Cancer Research and Treatment in September 2022, in women aged 60 years and above, the prevalence of breast cancer in Germany was 6.8% in women above 175 cm in height and 12.2% in women with a height of 171-175 cm. The high burden of breast cancer cases increases the demand for early detection and effective treatment, which is further anticipated to fuel the segment's growth.

Furthermore, the companies' rising focus on adopting key strategies to enter the market contributes to market growth. For instance, in January 2021, Hologic, Inc. acquired Somatex Medical Technologies for USD 64 million. This acquisition assists the company in providing a broad suite of innovative breast health solutions and expanding its breast marker portfolio with biopsy site markers and localization technologies. Furthermore, with this acquisition, the company intends to boost its sales presence in Europe by growing its direct channel in Germany and its regional and global distributor partner network.

Thus, the studied segment is anticipated to grow over the forecast period due to the aforementioned factors, such as the high prevalence of breast cancer among women and the increasing adoption of wire localization methods.

North America Expected to Dominate the Market

North America held a significant share of the breast lesion localization methods market in the past few years and is expected to show a similar trend over the forecast period. This is primarily due to the high burden of breast cancer cases coupled with robust healthcare infrastructure and increasing awareness about breast cancer.

In North America, United States is expected to hold a significant share during the forecast period in the market studied due to the high prevalence and incidence of breast cancer, robust healthcare infrastructure, and better reimbursement scenarios. The 2022 statistics published by BCRF expected about 287,850 new cases of breast cancer to be diagnosed in women in United States in 2022. As per the same source, in United States, the average risk of women developing breast cancer at some point in their lives is 13%. In recent years, the incidence rate of breast cancer has increased by 0.5% per year in United States. Additionally, per 2022 statistics published by the Canadian Cancer Society, about 28,600 Canadian women are expected to be diagnosed with breast cancer in 2022. Thus, the anticipated increase in breast cancer cases fuels the demand for diagnostics and surgical procedures for treating breast cancer and drives the growth in the breast lesion localization methods market over the years.

Furthermore, the rising product approvals in the region increase the availability of localization devices in the market, which is anticipated to boost market growth over the forecast period. For instance, in July 2022, Merit Medical System enrolled the first patient in a post-market, observational study to demonstrate the benefits of SCOUT, a wireless, radar-guided localization system for marking breast tumors, biopsy sites, and lymph nodes.

Thus, the studied market is expected to grow over the forecast period due to the aforementioned factors, such as the high burden of breast cancer and increasing product approvals in the region.

Competitive Landscape

The breast lesion localization methods market is consolidated and consists of a few major players. In terms of share, a few of the major players are currently dominating the market. Some of the players in the market studied are Becton, Dickinson and Company, Hologic Inc., Cook Medical, Merit Medical, and STERYLABS, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Breast Cancer and Breast Cancer Surgeries
    • 4.2.2 Technological Advancements in Breast Lesion Localization
    • 4.2.3 Increasing Awareness of Need for Early Detection of Breast Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Breast Lesion Localization Methods
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Localization Method
    • 5.1.1 Wire Localization
    • 5.1.2 Radioisotope Localization
    • 5.1.3 Magnetic Tracers Localization
    • 5.1.4 Other Localization Methods
  • 5.2 By Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Hologic Inc. (SOMATEX Medical Technologies)
    • 6.1.3 Cook Medical
    • 6.1.4 Merit Medical (Cianna Medical)
    • 6.1.5 STERYLAB SRL
    • 6.1.6 Danaher Corporation (Leica Biosystems)
    • 6.1.7 Theragenics Corporation (CP Medical Inc.)
    • 6.1.8 Elucent Medical
    • 6.1.9 Tsunami SRL
    • 6.1.10 MDL SRL
    • 6.1.11 MOLLI Surgical
    • 6.1.12 Argon Medical Devices
    • 6.1.13 Mermaid Medical A/S

7 MARKET OPPORTUNITIES AND FUTURE TRENDS